{"name": "Synosia Therapeutics",
 "permalink": "synosia-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/synosia-therapeutics",
 "homepage_url": "http://www.synosia.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "Synosis",
 "email_address": "julie.walters@tudor-reilly.com",
 "phone_number": "",
 "description": "Pharmaceutical Compounds",
 "created_at": "Tue May 05 21:09:06 UTC 2009",
 "updated_at": "Thu Oct 21 06:58:14 UTC 2010",
 "overview": "\u003Cp\u003ESynosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson\u0026#8217;s disease.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       49],
      "assets/images/resized/0004/3264/43264v1-max-150x150.png"],
     [[217,
       71],
      "assets/images/resized/0004/3264/43264v1-max-250x250.png"],
     [[217,
       71],
      "assets/images/resized/0004/3264/43264v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO \u0026 President",
    "person":
     {"first_name": "Ian",
      "last_name": "Massey",
      "permalink": "ian-massey",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Philippe",
      "last_name": "Lutz",
      "permalink": "philippe-lutz",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$91.5M",
 "funding_rounds":
  [{"round_code": "b",
    "source_url": "http://www.fiercebiotech.com/story/synosia-raises-29m-phase-ii-testing/2009-01-07",
    "source_description": "Synosia raises $29M for Phase II testing",
    "raised_amount": 29000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 1,
    "funded_day": null,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Aravis Ventures",
         "permalink": "aravis-ventures",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0004/8028/48028v2-max-150x150.png"],
             [[208,
               38],
              "assets/images/resized/0004/8028/48028v2-max-250x250.png"],
             [[208,
               38],
              "assets/images/resized/0004/8028/48028v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Investor Growth Capital",
         "permalink": "investor-growth-capital",
         "image":
          {"available_sizes":
            [[[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-150x150.png"],
             [[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-250x250.png"],
             [[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Swiss Helvetia Fund",
         "permalink": "swiss-helvetia-fund",
         "image":
          {"available_sizes":
            [[[150,
               97],
              "assets/images/resized/0004/7516/47516v1-max-150x150.jpg"],
             [[156,
               101],
              "assets/images/resized/0004/7516/47516v1-max-250x250.jpg"],
             [[156,
               101],
              "assets/images/resized/0004/7516/47516v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Versant Ventures",
         "permalink": "versant-ventures",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0004/6455/46455v2-max-150x150.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-250x250.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Abingworth",
         "permalink": "abingworth-management",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0003/6134/36134v2-max-150x150.jpg"],
             [[221,
               73],
              "assets/images/resized/0003/6134/36134v2-max-250x250.jpg"],
             [[221,
               73],
              "assets/images/resized/0003/6134/36134v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novo Ventures",
         "permalink": "novo-ventures",
         "image":
          {"available_sizes":
            [[[133,
               56],
              "assets/images/resized/0004/6080/46080v2-max-150x150.jpg"],
             [[133,
               56],
              "assets/images/resized/0004/6080/46080v2-max-250x250.jpg"],
             [[133,
               56],
              "assets/images/resized/0004/6080/46080v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "5AM Ventures",
         "permalink": "5am-ventures",
         "image":
          {"available_sizes":
            [[[150,
               104],
              "assets/images/resized/0004/7316/47316v2-max-150x150.jpg"],
             [[250,
               173],
              "assets/images/resized/0004/7316/47316v2-max-250x250.jpg"],
             [[288,
               200],
              "assets/images/resized/0004/7316/47316v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "unattributed",
    "source_url": "http://deals.venturebeat.com/2007/01/05/neurological-co-synosis-raises-325m/",
    "source_description": "Neurological co. Synosis raises $32.5M",
    "raised_amount": 32500000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 1,
    "funded_day": 5,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Versant Ventures",
         "permalink": "versant-ventures",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0004/6455/46455v2-max-150x150.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-250x250.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Abingworth",
         "permalink": "abingworth-management",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0003/6134/36134v2-max-150x150.jpg"],
             [[221,
               73],
              "assets/images/resized/0003/6134/36134v2-max-250x250.jpg"],
             [[221,
               73],
              "assets/images/resized/0003/6134/36134v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "5AM Ventures",
         "permalink": "5am-ventures",
         "image":
          {"available_sizes":
            [[[150,
               104],
              "assets/images/resized/0004/7316/47316v2-max-150x150.jpg"],
             [[250,
               173],
              "assets/images/resized/0004/7316/47316v2-max-250x250.jpg"],
             [[288,
               200],
              "assets/images/resized/0004/7316/47316v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novo A/S",
         "permalink": "novo-a-s",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0025/1103/251103v1-max-150x150.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-250x250.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "http://www.synosia.com/list-details.aspx?listguid=E8469572-06DC-475F-9815-2A91E1232F9A\u0026folderguid=801EEB72-27A8-495F-8A19-242E20F5F875",
    "source_description": "Synosia Therapeutics Raises $30M in Series C Financing",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 10,
    "funded_day": 12,
    "investments":
     [{"company":
        {"name": "UCB Pharma",
         "permalink": "ucb-pharma",
         "image":
          {"available_sizes":
            [[[65,
               61],
              "assets/images/resized/0007/0964/70964v1-max-150x150.jpg"],
             [[65,
               61],
              "assets/images/resized/0007/0964/70964v1-max-250x250.jpg"],
             [[65,
               61],
              "assets/images/resized/0007/0964/70964v1-max-450x450.jpg"]],
           "attribution": null}},
       "financial_org": null,
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Versant Ventures",
         "permalink": "versant-ventures",
         "image":
          {"available_sizes":
            [[[150,
               30],
              "assets/images/resized/0004/6455/46455v2-max-150x150.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-250x250.jpg"],
             [[190,
               38],
              "assets/images/resized/0004/6455/46455v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "5AM Ventures",
         "permalink": "5am-ventures",
         "image":
          {"available_sizes":
            [[[150,
               104],
              "assets/images/resized/0004/7316/47316v2-max-150x150.jpg"],
             [[250,
               173],
              "assets/images/resized/0004/7316/47316v2-max-250x250.jpg"],
             [[288,
               200],
              "assets/images/resized/0004/7316/47316v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novo A/S",
         "permalink": "novo-a-s",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0025/1103/251103v1-max-150x150.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-250x250.png"],
             [[250,
               99],
              "assets/images/resized/0025/1103/251103v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Aravis Ventures",
         "permalink": "aravis-ventures",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0004/8028/48028v2-max-150x150.png"],
             [[208,
               38],
              "assets/images/resized/0004/8028/48028v2-max-250x250.png"],
             [[208,
               38],
              "assets/images/resized/0004/8028/48028v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Investor Growth Capital",
         "permalink": "investor-growth-capital",
         "image":
          {"available_sizes":
            [[[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-150x150.png"],
             [[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-250x250.png"],
             [[107,
               31],
              "assets/images/resized/0002/9321/29321v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Swiss Helvetia Fund",
         "permalink": "swiss-helvetia-fund",
         "image":
          {"available_sizes":
            [[[150,
               97],
              "assets/images/resized/0004/7516/47516v1-max-150x150.jpg"],
             [[156,
               101],
              "assets/images/resized/0004/7516/47516v1-max-250x250.jpg"],
             [[156,
               101],
              "assets/images/resized/0004/7516/47516v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition":
  {"price_amount": 121500000.0,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss\u0026utm_source=rss",
   "source_description": "Biotie buys CNS developer Synosia in $121.5M deal  Read more: Biotie buys CNS developer Synosia in $121.5M deal - FierceBiotech http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss\u0026utm_source=rss#ixzz1A",
   "acquired_year": 2011,
   "acquired_month": 1,
   "acquired_day": 11,
   "acquiring_company":
    {"name": "Biotie Therapies",
     "permalink": "biotie-therapies",
     "image":
      {"available_sizes":
        [[[150,
           64],
          "assets/images/resized/0011/7092/117092v1-max-150x150.png"],
         [[155,
           67],
          "assets/images/resized/0011/7092/117092v1-max-250x250.png"],
         [[155,
           67],
          "assets/images/resized/0011/7092/117092v1-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "Headquarters",
    "address1": "Aeschenvorstadt 36",
    "address2": "CH-4051",
    "zip_code": "",
    "city": "Basel",
    "state_code": null,
    "country_code": "CHE",
    "latitude": 47.5525264,
    "longitude": 7.5930992}],
 "milestones":
  [{"description": "UCB and Synosia Therapeutics sign strategic alliance in neurology ",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 12,
    "source_url": "http://www.synosia.com/list-details.aspx?listguid=34DC3D71-78BA-4A8C-B82A-AE36DF924523\u0026folderguid=801EEB72-27A8-495F-8A19-242E20F5F875",
    "source_text": "",
    "source_description": "UCB and Synosia Therapeutics sign strategic alliance in neurology ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synosia Therapeutics",
      "permalink": "synosia-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}